Program Description

Multiple anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs) have gained Emergency Use Authorization (EUA) from the US Food and Drug Administration for both treatment and prevention of coronavirus disease 2019 (COVID-19), though the presence of multiple new variants and subvariants has rapidly shifted mAb efficacy and EUA status. Clinicians struggle to remain up to date with a rapidly changing field that has remained a public health concern. A panel of experts will present data on and discuss current evidence and regulatory status for these anti-SARS-CoV-2 mAbs and available antivirals, updates to National Institutes of Health guidelines on patient identification and stratification for both treatment and prevention, implementation through COVID-19 clinic models, and strategies to reduce health care disparities. The panel will utilize additional experts to augment discussion and provide expertise on multiple topics.

Target Audience

This activity is intended to educate infectious disease, internal medicine, and other clinicians involved in the management of patients who are at heightened risk for poor outcomes for COVID-19.

Learning Objectives

Upon completion of this activity, the participant should be better able to:

  • Describe the clinical profiles, trial data, and regulatory status for anti-SARS-CoV-2 mAbs for preexposure prophylaxis and treatment
  • Identify candidates for preexposure prophylaxis or treatment with anti-SARS-CoV-2 mAbs, including immunocompromised patients
  • Collaborate with patients and other clinicians to overcome barriers to the use of anti-SARS-CoV-2 mAbs for preexposure prophylaxis or treatment


Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA (University of California, Los Angeles) Medical Center
Investigator, Lundquist Institute
Professor of Medicine
David Geffen School of Medicine at UCLA
Torrance, California

Raymund R. Razonable, MD, FIDSA, FAST
Professor of Medicine
Program Director, Infectious Diseases Fellowship Program
Vice Chair, Division of Infectious Diseases
Mayo Clinic College of Medicine and Science
Rochester, Minnesota

Phyllis Tien, MD
Professor of Medicine, Division of Infectious Diseases
University of California (UC), San Francisco
Staff Physician
San Francisco Veterans Affairs Health Care System
San Francisco, California

“Call-A-Colleague” Faculty

Lucy Horton, MD, MPH
Associate Professor of Medicine
Infectious Disease Specialist
UC San Diego Health
San Diego, California

Lewis Teperman, MD, FACS
Vice Chair, Organ Transplant Surgery
Director, Organ Transplantation
Professor of Surgery and Medicine
Zucker School of Medicine at Hofstra
Northwell Health
New York, New York

Charles P. Vega, MD, FAAFP
Clinical Professor, Family Medicine
Director, UC Irvine Program in Medical Education for the Latino Community
Associate Dean, School of Medicine
University of California, Irvine
Irvine, California

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.5 contact hours (which includes 0.1 hour(s) of pharmacology).

Instructions to Receive Credit

In order to receive credit, participants must complete the following:

  1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
  2. Complete the Preactivity Questions.
  3. Review the activity content.
  4. Achieve a grade of 70% on the Postactivity Test Questions and complete the Evaluation.

Disclosure of Conflicts of Interest

Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Eric S. Daar, MD - Consultant Fees: Gilead, Merck; Contracted Research: Gilead, ViiV
Lucy Horton, MD - Consulting Fees: Gilead, GSK
Raymund R. Razonable, MD - Contracted Research: Gilead (funds to institution), Roche, Regeneron; Honoraria: Member of DSMB for Novartis
Lewis Teperman, MD - Nothing to disclose
Phyllis Tien, MD - Contracted Research: Gilead, Merck
Charles P. Vega, MD - Consulting fees: GlaxoSmithKline plc., Johnson & Johnson

The planners and managers at Global and Integritas Communications have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Global Contact Information

For information about the approval of this program, please contact Global at 303-395-1782 or

Begin Activity
available resources
meeting slides
linked resources
Suggested Reading
Call a Colleague

A Call to Action

Monoclonal Antibodies for the Prevention and Treatment of COVID-19